全文获取类型
收费全文 | 1244篇 |
免费 | 123篇 |
国内免费 | 31篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 6篇 |
妇产科学 | 6篇 |
基础医学 | 71篇 |
口腔科学 | 15篇 |
临床医学 | 161篇 |
内科学 | 383篇 |
皮肤病学 | 6篇 |
神经病学 | 82篇 |
特种医学 | 6篇 |
外科学 | 81篇 |
综合类 | 64篇 |
预防医学 | 50篇 |
眼科学 | 12篇 |
药学 | 386篇 |
1篇 | |
中国医学 | 14篇 |
肿瘤学 | 52篇 |
出版年
2024年 | 1篇 |
2023年 | 12篇 |
2022年 | 22篇 |
2021年 | 31篇 |
2020年 | 55篇 |
2019年 | 53篇 |
2018年 | 61篇 |
2017年 | 50篇 |
2016年 | 53篇 |
2015年 | 62篇 |
2014年 | 88篇 |
2013年 | 235篇 |
2012年 | 79篇 |
2011年 | 76篇 |
2010年 | 69篇 |
2009年 | 72篇 |
2008年 | 59篇 |
2007年 | 81篇 |
2006年 | 66篇 |
2005年 | 47篇 |
2004年 | 51篇 |
2003年 | 29篇 |
2002年 | 18篇 |
2001年 | 11篇 |
2000年 | 4篇 |
1999年 | 5篇 |
1998年 | 3篇 |
1997年 | 2篇 |
1996年 | 2篇 |
1991年 | 1篇 |
排序方式: 共有1398条查询结果,搜索用时 15 毫秒
1.
动脉粥样硬化是导致心血管疾病及死亡的主要原因,严重危害人类健康。目前预防动脉粥样硬化
的机制众多,以调脂代谢降低炎症反应为基础较多。本文将近几年他啶类、贝特类、烟酸类以及中药等调脂药物
对预防动脉粥样硬化的药理作用以及临床应用研究现状做一综述。 相似文献
的机制众多,以调脂代谢降低炎症反应为基础较多。本文将近几年他啶类、贝特类、烟酸类以及中药等调脂药物
对预防动脉粥样硬化的药理作用以及临床应用研究现状做一综述。 相似文献
2.
他汀类药物对心血管的保护作用 总被引:6,自引:0,他引:6
他汀类药物(statins)被研制出来的最初目的是降低血脂,但是现在发现它不仅具有降低血脂的作用,还具有很多其他的作用包括改善内皮细胞功能的紊乱,提高内皮源性一氧化氮合成酶的生物活性,抑制血管平滑肌细胞的增殖,抗氧化作用,抗炎作用,降低血压,逆转心血管系统的重构。充分理解statins的多效性作用及机制有利于它更好的在临床中被应用于心血管系统的预防和治疗。 相似文献
3.
A. UNDAS M. CELINSKA-LÖWENHOFF T. LÖWENHOFF A. SZCZEKLIK 《Journal of thrombosis and haemostasis》2006,4(5):1029-1036
BACKGROUND: Aspirin increases fibrin clot porosity and susceptibility to lysis. It is unknown whether other drugs, in combination with aspirin, used in the treatment of coronary artery disease (CAD) might affect clot structure and resistance to lysis. AIM: The aim of the study was to assess the effects of statins, fibrates, or angiotensin-converting enzyme inhibitors (ACEIs) on fibrin clot properties. PATIENTS AND METHODS: In a randomized double-blind study, men with advanced CAD taking low-dose aspirin were assigned to receive one of the four drugs: simvastatin 40 mg day(-1) (n = 13), atorvastatin 40 mg day(-1) (n = 12), fenofibrate 160 mg day(-1) (n = 12), and quinapril 10 mg day(-1) (n = 11) for 28 +/- 2 days. Moreover, CAD patients (n = 13) taking aspirin (75 mg day(-1)) for 8 weeks were studied after additional 4 weeks on an open-label basis. Thirty men served as healthy controls. Plasma clot permeability and tissue plasminogen activator-induced fibrinolysis were evaluated at baseline and after drug administration. RESULTS: Permeability increased following the administration of simvastatin (by 20%; P = 0.01), atorvastatin (by 22%; P = 0.001), fenofibrate (by 16%; P = 0.02), and quinapril (by 13%; P = 0.04) like for aspirin (P < 0.001). Turbidity analysis showed that administration of any of the drugs was associated with higher maximum absorbancy, suggesting thicker fibers, and shorter fibrinolysis time (P < 0.001). Post-treatment reduction in lysis time correlated with an increase in clot porosity in all the groups (r from 0.42 to 0.61; P from 0.01 to 0.001). CONCLUSIONS: Statins, fibrates, and ACEIs may increase plasma clot permeability and susceptibility to fibrinolysis in CAD patients receiving aspirin. This novel antithrombotic mechanism might contribute to clinical benefits of the drugs tested. 相似文献
4.
Milica Zrnic Ciric Miodrag Ostojic Ivana Baralic Jelena Kotur-Stevuljevic Brizita I. Djordjevic Stana Markovic Stefan Zivkovic Ivan Stankovic 《Nutrients》2021,13(3)
Dietary supplementation with sugar cane derivates may modulate low-density lipoprotein cholesterol (LDL-C) and proprotein convertase subtilisin/kexin type 9 (PCSK9) levels. The purpose of this study was to determine if dietary supplement (DS), containing Octacosanol (20 mg) and vitamin K2 (45 µg), could restore the disrupted physiologic relation between LDL-C and serum PCSK9. Double-blind, randomized, placebo-controlled, single-center study including 87 patients on chronic atorvastatin therapy was conducted. Eighty-seven patients were randomized to receive DS (n = 42) or placebo (n = 45), and followed for 13 weeks. Serum PCSK9 levels, lipid parameters and their relationship were the main efficacy endpoints. The absolute levels of PCSK9 and LDL-C were not significantly different from baseline to 13 weeks. However, physiologic correlation between % change of PCSK9 and % change of LDL-C levels was normalized only in the group of patients treated with DS (r = 0.409, p = 0.012). This study shows that DS can restore statin disrupted physiologic positive correlation between PCSK9 and LDL-C. Elevated PCSK9 level is an independent risk factor so controlling its rise by statins may be important in prevention of cardiovascular events. 相似文献
5.
新型调脂药ezetimibe--胆固醇吸收的选择性抑制剂 总被引:3,自引:0,他引:3
传统的树脂类、贝特类等药物因为不良反应大,降低胆固醇效果差而不易被病人接受。他汀类药物降低胆固醇效果好,但某些病人单用他汀类药物不能有效降低体内胆固醇水平。因此本文介绍了新近在美国上市的ezetimibe,一种新型胆固醇吸收的选择性抑制剂,在单用或与他汀类药物联用时,都能稳定降低血浆低密度脂蛋白胆固醇(LDL-C)水平,为临床治疗高脂血症提供了新的选择。 相似文献
6.
目的: 观察急性心肌梗塞(AMI)患者服用倍他乐克、他汀类药物后对心脏的保护作用,了解其对AMI早期治疗及预后的重要意义.方法: 分析因AMI入院者服用倍他乐克、他汀类降脂药物、抗血小板药及硝酸酯类药物的情况和血清胆固醇水平;并与只服用抗血小板药及硝酸酯类药物的AMI患者比较.结果: 应用倍他乐克、他汀类药物治疗并追踪4~12个月,患者心功能明显地缓解,血脂水平正常,心电图正常,心脏在原基础上无增大表现.结论: 倍他乐克、他汀类药物的早期应用对AMI患者的治疗及预后有益,对防止心肌肥大及心室重塑有效. 相似文献
7.
冠心病患者降脂药物的应用评价 总被引:4,自引:0,他引:4
孟磊 《中国医院用药评价与分析》2004,4(4):207-209
目的:评价各类降脂药物在冠心病治疗中的研究进展及临床应用情况.方法:查阅近期国外相关文献进行综述、评价.结果与结论:降脂药物主要分为他汀类、苯氧芳酸类、烟酸类及胆酸螯合剂等.降脂治疗在冠心病的治疗中占有重要地位,及早合理地应用降脂药物,可以使冠心病患者获得长期的受益. 相似文献
8.
9.
《Expert review of anticancer therapy》2013,13(11):1559-1568
Melanoma is one of the few tumors that have increased in incidence over the last few decades. Strategies devoted solely to protecting against ultraviolet radiation have, at best, had a modest impact on the development of melanoma. Chemoprevention is an under-explored approach that could significantly decrease the morbidity and mortality from this deadly cancer. However, the scientific and logistical challenges of performing clinical studies in chemoprevention require innovative approaches to prove the effectiveness of putative preventive agents. There are several pharmacological and nutriceutical agents that are mechanistically linked to events in melanoma carcinogenesis that are candidates for advanced human studies. We will review the data for several promising agents, including statins, curcumin, resveratrol, silymarin and green tea, and discuss some importance issues and concepts that should be considered in any melanoma chemoprevention strategy. 相似文献
10.
Autosomal Dominant Familial Hypercholesterolaemia (FH) is the commonest inherited disorder of lipoprotein metabolism. Untreated monogenic FH caused by mutations in the LDLR, APOB or PCSK9 genes result in early onset cardiovascular death (below the age of 60 years). In the UK the prevalence of heterozygous FH is 1 in 270 and homozygous FH is 160,000 approximately.The introduction of statins nearly three decades ago has altered the natural history of FH, with a significant reduction of cardiovascular related morbidity and mortality. There is increasing evidence that early childhood interventions such as lifestyle choices, healthy eating and commencing statins by the age of 10 years would potentially prevent early onset cardiovascular disease and mortality in monogenic FH. The medium term safety of statins in children has been demonstrated. The UK paediatric FH register data has shown that children with FH are less obese than the normal population and the register aims to monitor the longer-term safety of statins in children with FH. Child-parent screening would potentially benefit the child and enables identifying a parent with FH, before the onset of a life threatening cardiovascular event. In addition, genetic cascade testing of relatives of an affected individual has been shown to be highly cost effective.We review the current literature with brief updates on genetics, the UK paediatric FH register data, published recommendations for the management of homozygous and heterozygous FH, lipid lowering therapies in children and screening for FH in childhood. 相似文献